Professionals 248 Users Online

Renal Anemia Treatment Market

Global Market Study on Renal Anemia Treatment: Development of Novel HIF Stabilizers & Approval of Cost-effective Biosimilar Drugs Expected to Push Growth

Renal Anemia Treatment Market Segmented By Iron Supplements, Erythrocyte Stimulating Agents like Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa Product Type with Oral and Parenteral Route of Administration

Cost-effectiveness of Biosimilar Drugs to Push Growth of the Renal Anemia Treatment Market

  • Pharmaceutical Companies are Focusing on Research and Development of Novel Products

Multinational pharmaceutical companies that develop drugs for renal anemia treatment will play an important role in improving access to quality care in the developing countries. Pharmaceutical companies in the field of renal anemia treatment have reported strong financial results in the past few years. For instance, Novartis’ Binocrit used for renal anemia treatment has recorded significant growth in revenue in the last few years.

The company expects that the revenue from the product will increase further in the coming years. Increasing number of pharmaceutical companies and increasing research and development with the aim of developing novel drugs for renal anemia treatment will contribute towards the growth of the concerned market during the forecast period.

  • Unlocking Potential for Biosimilar Medicine for Renal Anemia Treatment

Biologics will play a significant role in the renal anemia treatment care market across the globe. The emergence of biologics and growing demand for biosimilar medicines across the world will create new opportunities for the players operating in the renal anemia treatment market. Biosimilar drugs are a cost-effective method of renal anemia treatment. They also allow for greater patient access, which will further push the growth of the renal anemia treatment market during the forecast period.

FDA approval for various biosimilars for renal anemia treatment in the past few years will lead to huge benefits for patients suffering from renal anemia. For instance, in 2018, FDA approved epoetin alfa-epbx (Retacrit) manufactured by Hospira, Inc, as a biosimilar to epoetin alfa (Epogen/Procrit) for the treatment of renal anemia caused by chronic kidney diseases.

  • Collaboration among Key Pharmaceutical Industries to Develop Novel Drugs for Renal Anemia Treatment

Despite the many advancements in biomedical research and healthcare systems, the global healthcare burden is increasing globally. In order to meet healthcare challenges and develop novel drugs for renal anemia treatment, various pharmaceutical industries have developed a new business model to increase profitability and decrease cost of failure. New collaborative models within the pharmaceutical industry will further help to reshape the research and development of drugs for renal anemia treatment.

Over the years, the strategy of mergers, acquisitions and collaborations within the pharmaceutical industry has continued to grow and has paved way for the development of drugs for renal anemia treatment. Open collaborations and new business models, such as joint ventures between pharmaceutical companies and other external entities, will push pharmaceutical research by facilitating partnerships involving academia and the public and private sector.


Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample


Renal anemia occurs when the body has fewer red blood cells than normal. In case of anemia, red blood cells carry less oxygen than required to tissues and organs, especially to heart and brain. Anemia is a frequent complication caused in patients suffering from chronic kidney disease and occurs in more than 90% of patients receiving renal replacement therapy.

Anemia of chronic kidney disease is caused by a decrease in erythropoietin production and anemia tends to get worse as the chronic kidney disease progresses.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

About the Report

PMR conducted a research study on renal anemia treatment market for the forecast period 2018 to 2026. The renal anemia treatment market report offers a comprehensive evaluation of the business opportunities prevailing in the renal anemia treatment market along with insights on prevalence of renal anemia in top countries.

The global report on renal anemia treatment also explains the key regulations for drug approval and pipeline assessment. The report on renal anemia treatment also elaborates on the macroeconomic factors influencing the dynamics of renal anemia treatment market and its futuristic potential.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology


The report offers a comprehensive taxonomy of renal anemia treatment market based on product type, route of administration, distribution channel and end user and region. Product types covered under the current research scope of report include iron supplements and erythrocyte stimulating agents.

The erythrocyte stimulating agents segment is further segmented into epoetin alfa, epoetin beta and darbepoetin alfa. By route of administration, the renal anemia treatment market is classified into oral and parenteral. The global renal anemia treatment market report has been segmented by distribution channels into hospitals pharmacies, retail pharmacies and mail order pharmacies.

The renal anemia treatment market has been analyzed across regions of North America, Latin America, Europe, Asia-Pacific excluding China, China and Middle East and Africa.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Additional Questions Answered

Some of the additional questions addressed in this report on renal anemia treatment market-

  • What are the major factors influencing the growth of renal anemia treatment market?
  • What prescription pattern is followed by doctors dealing with renal anemia treatment cases?
  • What is prevalence and treatment seeking rate of renal anemia in top countries?
  • What are key regulations for drug approval and products in pipeline for the renal anemia treatment by geography?

Research Methodology

To estimate the market size of renal anemia treatment market, we followed an epidemiology based approach. Following are some of the steps we followed to calculate base year market size of renal anemia treatment market. Initially, we studied the prevalence of diseases in top 20 countries to analyze the potential patient population seeking renal anemia treatment. The prevalence of renal anemia among adult population in different countries was analyzed through in-depth secondary research.

Culmination of secondary and primary research helped in zeroing on treatment seeking rates for renal anemia among the potential patient population in different countries. The process for this included primary interviews with nephrologists and nurses across leading hospitals in each of these 20 countries. The annual cost for renal anemia treatment was also validated through primary research.

- Companies Covered in This Report -

  • Amgen Inc.
  • Vifor Pharma Management Ltd.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Sandoz International GmbH (Novartis AG)
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • Teva Pharmaceutical Industries Ltd.
  • AMAG Pharmaceuticals
  • Rockwell Medical
  • Akebia Therapeutics
  • Others.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate